QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data

Impact · against what's priced in

uniQure faces severe valuation risk following FDA allegations of data manipulation and the labeling of its lead asset, AMT-130, as a 'failed therapy.' GeneDx is under pressure due to significant losses and legal action stemming from its Fabric Genomics acquisition.

QURE−0.90

No priced-in read yet